BATON ROUGE, La., Oct. 18, 2023 (GLOBE NEWSWIRE) -- Amedisys, Inc. (NASDAQ: AMED), a leading provider of home health, hospice and high-acuity care in the home, is proud to celebrate National Quality Week October 15-21, 2023. This week-long observance serves as an opportunity for Amedisys to recognize and highlight the organization's commitment to delivering the highest standard of quality care.
During National Quality Week, Amedisys will focus on the importance of quality in healthcare by raising awareness among healthcare professionals and patients. The aim is to emphasize the significance of quality improvement initiatives, patient safety and continuous learning within the organization, while highlighting some of its industry-leading quality scores.
“At Amedisys and Contessa, our primary focus has always been on providing excellent and personalized care for our patients," said Dr. Amy Moss, Senior Vice President of Clinical Quality for Hospice at Amedisys. "National Quality Week provides us with a platform to showcase our unwavering dedication to quality and reinforces our commitment to delivering exceptional healthcare services to our patients. Congratulations to our outstanding clinicians for their dedication to clinical distinction and quality.”
The National Healthcare Quality Week was established by the National Association of Healthcare Quality in 1985, among other things, to recognize and celebrate the contribution of healthcare quality experts in their various organizations. Every year, N.A.H.Q. holds a week-long celebration in collaboration with groups dedicated to improving healthcare quality.
For more information about Amedisys and to learn more about our commitment to quality, visit www.amedisys.com.
About Amedisys
Amedisys, Inc. is a leading healthcare at home Company delivering personalized home health, hospice, and high-acuity care services. Amedisys is focused on delivering the care that is best for our patients, whether that is home-based personal care; inpatient hospital, palliative, and skilled nursing facility (“SNF”) care in their homes; recovery and rehabilitation after an operation or injury; care focused on empowering them to manage a chronic disease; or hospice care at the end of life. More than 3,000 hospitals and 102,000 physicians nationwide have chosen Amedisys as a partner in post-acute care. Founded in 1982, headquartered in Baton Rouge, LA with an executive office in Nashville, TN, Amedisys is a publicly held company. With approximately 20,000 employees, in 532 care centers in 37 states and the District of Columbia, Amedisys is dedicated to delivering the highest quality of care to the doorsteps of more than 465,000 patients in need every year, performing more than 11.2 million visits annually. For more information about the Company, please visit: www.amedisys.com.
Contact: | |
Nick Muscato | Kendra Kimmons |
Amedisys, Inc. | Amedisys, Inc. |
Chief Strategy Officer | Media Relations |
615.928.5452 | 225.299.3720 |
This email address is being protected from spambots. You need JavaScript enabled to view it. | This email address is being protected from spambots. You need JavaScript enabled to view it. |
Last Trade: | US$91.91 |
Daily Change: | 0.33 0.36 |
Daily Volume: | 226,295 |
Market Cap: | US$3.010B |
February 26, 2025 November 06, 2024 August 21, 2024 July 24, 2024 April 24, 2024 |
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORETerns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MOREEnd of content
No more pages to load